Molecular monitoring of lung allograft health: is it ready for routine clinical use?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F23%3A10471274" target="_blank" >RIV/00064203:_____/23:10471274 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10471274
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Y5wEMX2Iox" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Y5wEMX2Iox</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1183/16000617.0125-2023" target="_blank" >10.1183/16000617.0125-2023</a>
Alternative languages
Result language
angličtina
Original language name
Molecular monitoring of lung allograft health: is it ready for routine clinical use?
Original language description
Maintenance of long-term lung allograft health in lung transplant recipients (LTRs) requires a fine balancing act between providing sufficient immunosuppression to reduce the risk of rejection whilst at the same time not over-immunosuppressing individuals and exposing them to the myriad of immunosuppressant drug side-effects that can cause morbidity and mortality. At present, lung transplant physicians only have limited and rather blunt tools available to assist them with this task. Although therapeutic drug monitoring provides clinically useful information about single time point and longitudinal exposure of LTRs to immunosuppressants, it lacks precision in determining the functional level of immunosuppression that an individual is experiencing. There is a significant gap in our ability to monitor lung allograft health and therefore tailor optimal personalised immunosuppression regimens. Molecular diagnostics performed on blood, bronchoalveolar lavage or lung tissue that can detect early signs of subclinical allograft injury, differentiate rejection from infection or distinguish cellular from humoral rejection could offer clinicians powerful tools in protecting lung allograft health. In this review, we look at the current evidence behind molecular monitoring in lung transplantation and ask if it is ready for routine clinical use. Although donor-derived cell-free DNA and tissue transcriptomics appear to be the techniques with the most immediate clinical potential, more robust data are required on their performance and additional clinical value beyond standard of care.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Respiratory Review
ISSN
0905-9180
e-ISSN
1600-0617
Volume of the periodical
32
Issue of the periodical within the volume
170
Country of publishing house
CH - SWITZERLAND
Number of pages
16
Pages from-to
230125
UT code for WoS article
001115799500001
EID of the result in the Scopus database
2-s2.0-85177817486